• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    2/14/23 4:29:49 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHL alert in real time by email
    SC 13G/A 1 tm236041d19_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

       

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

       

    Achilles Therapeutics plc

    (Name of Issuer)

     

    American Depositary Shares, each representing one Ordinary Share, £0.001 par value

    (Title of Class of Securities)

       

    00449L102**

     

    (CUSIP Number)

      

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x  Rule 13d-1(b)
         
      ¨ Rule 13d-1(c)
         
      ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** This CUSIP number applies to the Issuer’s American Depositary Shares, evidenced by American Depositary Receipts, each representing one ordinary share of the Issuer.

      

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 00449L102 

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,608,089 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,608,089 (1)  

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,608,089 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.9%(2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s American Depositary Shares, each representing one Ordinary Share £0.001 par value (“ADS”), is comprised of 1,608,089 ADSs owned by certain private investment vehicles managed by Redmile Group, LLC, which ADSs may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 40,938,763 Ordinary Shares issued and outstanding as of September 30, 2022, as reported by the Issuer in its Unaudited Condensed Consolidated Financial Statements of Achilles Therapeutics plc for the three and nine month periods ended September 30, 2022, an exhibit to the Form 6-K filed with the Securities and Exchange Commission on November 8, 2022 (the “Form 6-K”).

     

     

     

     

    CUSIP No. 00449L102

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,608,089 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,608,089 (3)  

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,608,089 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.9%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

    (3) Jeremy C. Green’s beneficial ownership of ADSs is comprised of 1,608,089 ADSs owned by certain private investment vehicles managed by Redmile Group, LLC, which ADSs may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 40,938,763 Ordinary Shares outstanding as of September 30, 2022, as reported by the Issuer in the Form 6-K.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Achilles Therapeutics plc

     

    (b)Address of Issuer’s Principal Executive Offices

     

    245 Hammersmith Road

    London W6 8PW

    United Kingdom

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    American Depositary Shares, each representing one Ordinary Share, £0.001 par value

     

    (e)CUSIP Number

     

    The CUSIP Number is 00449L102. This CUSIP applies to the American Depositary Shares, evidenced by American Depositary Receipts, each representing one Share. No CUSIP has been assigned to the Ordinary Shares.

     

     

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 1,608,089 *
    Jeremy C. Green – 1,608,089 *

     

    (b)Percent of class:

     

    Redmile Group, LLC – 3.9%**
    Jeremy C. Green – 3.9%**

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    1,608,089 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,608,089 *

     

     

     

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    1,608,089 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,608,089 *

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s ADSs is comprised of 1,608,089 ADSs owned by certain private investment vehicles managed by Redmile Group, LLC, which ADSs may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    **Percentage based on 40,938,763 Ordinary Shares outstanding as of September 30, 2022, as reported by the Issuer in the Form 6-K.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

     

     

    Redmile Group, LLC

     

         
      By:   /s/ Jeremy C. Green
         

    Name: Jeremy C. Green

    Title: Managing Member

     

     

          /s/ Jeremy C. Green
         

    Jeremy C. Green 

     

     

     

    Get the next $ACHL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL

    DatePrice TargetRatingAnalyst
    4/5/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

    LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation. Th

    2/28/25 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

    - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data

    12/24/24 9:30:00 AM ET
    $ACHL
    $AZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company's ADSs. The Company's ADSs will continue to trade under the symbol "ACHL." The approval by Nasdaq w

    11/19/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Achilles Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Achilles Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously

    4/5/24 7:22:16 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    SEC Filings

    View All

    SEC Form 15-12G filed by Achilles Therapeutics plc

    15-12G - Achilles Therapeutics plc (0001830749) (Filer)

    3/21/25 9:41:03 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Achilles Therapeutics plc

    6-K - Achilles Therapeutics plc (0001830749) (Filer)

    3/20/25 5:30:00 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Achilles Therapeutics plc

    S-8 POS - Achilles Therapeutics plc (0001830749) (Filer)

    3/19/25 4:16:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Leadership Updates

    Live Leadership Updates

    View All

    Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

    LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022. James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals

    6/30/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

    LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities. Bernhard is a veteran biotechnology and pharmaceutical executive with more than three decades in senior leadership roles. He most recently served as CEO of Biotest AG in Germany and also served as chairman of the board of directors at Symphogen A/S, Denmark until its acquisition by Servier SA in June 2

    5/4/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

    LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). "We are very pleased to welcome leading experts Dr. Gros and Dr. Creelan to our Scientific Advisory Board. With two ongoing clinical trials, CHIRON in non-small cell lung cancer (NSCLC) and THETIS in melanoma, their extensive research experience and deep clinical expertise with cell-based immunotherapies for the treatment of solid tumors will be invaluable as we continue to advance the clinic

    2/7/22 7:30:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achilles Therapeutics plc

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    11/14/24 4:23:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Achilles Therapeutics plc

    SC 13G - Achilles Therapeutics plc (0001830749) (Subject)

    9/25/24 7:14:31 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    3/29/24 4:30:59 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Financials

    Live finance-specific insights

    View All

    Achilles Therapeutics Reports Third Quarter 2024 Financial Results

    – Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.Achilles Chief Scientific Officer, Sergio Quezada, presented "Targeting Clonal Neoantigens with Pre

    11/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

    – Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

    8/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/

    5/8/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care